Five Prime Therapeutics (FPRX) Tops Q4 EPS by 96c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of $10.63, $0.96 better than the analyst estimate of $9.67. Revenue for the quarter came in at $363.34 million versus the consensus estimate of $354.16 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Movano (MOVE) Misses Q2 EPS by 195c